Buy Buserelin-depot lyophilisate for the preparation of suspension intramuscularly 3.75 mg in pharmacies
Buserelin-depot Buy Buserelin-depot in pharmacies DOSAGE FORMS lyophilisate for preparing a suspension for intramuscular injection. entered prolong. active 3.75 mg lyophilized powder for the preparation of intramuscular solution 3.75 mg
MANUFACTURERS Deco Company (Russia) Pharm-Sintez (Russia)
GROUP Antiandrogens
COMPOSITION Active ingredient: buserelin acetate 3.75 mg in the form of a free peptide.
INTERNATIONAL NON-PROPENTED NAME Buserelin
SYNONYMS Buserelin, Buserelin FSintez, Buserelin-long FS, Buserelin acetate solution
PHARMACOLOGICAL ACTION Pharmacodynamics. A synthetic analogue of natural gonadotropin-releasing hormone (GnRH). Buserelin competitively binds to the receptors of the cells of the anterior pituitary gland, causing a short-term increase in the level of sex hormones in the blood plasma. Further use of therapeutic doses of the drug leads (on average after 12-14 days) to a complete blockade of the gonadotropic function of the pituitary gland, thus inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). As a result, there is a suppression of the synthesis of sex hormones in the gonads, which is manifested by a decrease in the concentration of estradiol in the blood plasma to post-menopausal values in women and a decrease in testosterone content to a post-castration level in men. The concentration of testosterone with continuous treatment for 2-3 weeks decreases to the level characteristic of the orchiectomy state, i.e. pharmacological castration is caused. Pharmacokinetics. Bioavailability is high. The maximum plasma concentration is reached approximately 2-3 hours after intramuscular administration and remains at a level sufficient to inhibit the synthesis of gonadotropins by the pituitary gland for at least 4 weeks.
INDICATIONS FOR USE Hormone -dependent prostate cancer, breast cancer, endometriosis (pre- and postoperative periods), uterine fibroids, endometrial hyperplastic processes, infertility treatment (during an in vitro fertilization (IVF) program.
CONTRAINDICATIONS Pregnancy, breastfeeding, hypersensitivity to the components of the drug.
SIDE EFFECTS Allergic reactions: urticaria, skin hyperemia, rarely - angioedema. In women, typical adverse reactions are a manifestation of the achieved hypoestrogenic state - “pharmacological menopause”: From the central nervous system: frequent mood swings, sleep disturbances, depression, headache. From the endocrinological status: hot flashes, increased sweating, vaginal dryness, decreased libido, pain in the lower abdomen, demineralization of bones, rarely - menstrual-like bleeding (usually during the first weeks of treatment). In men, during the treatment of prostate cancer - during the first 2-3 weeks after the first injection, it can cause exacerbation and progression of the underlying disease, which is associated with stimulation of the synthesis of gonadotropins and, accordingly, testosterone, gynecomastia, a transient increase in the concentration of androgens in the blood (rarely - ossalgia , urinary retention, renal edema, muscle weakness in the lower extremities, lymphostasis). Other: in isolated cases (the cause-and-effect relationship has not been clearly established) - pulmonary embolism, dyspeptic disorders.
INTERACTION The simultaneous use of Buserelin with drugs containing sex hormones (for example, in the mode of ovulation induction) may contribute to the occurrence of ovarian hyperstimulation syndrome. With simultaneous use, Buserelin may reduce the effectiveness of hypoglycemic agents.
DOSAGE AND ADMINISTRATION For hormone-dependent prostate cancer: 3.75 mg intramuscularly (IM) every 4 weeks; In the treatment of endometriosis, endometrial hyperplastic processes: 3.75 mg IM once every 4 weeks. Treatment begins in the first five days of the menstrual cycle. Duration of treatment - 4-6 months; For the treatment of uterine fibroids: 3.75 mg IM once every 4 weeks. Treatment begins in the first five days of the menstrual cycle. Duration of treatment - 3 months before surgery, in other cases - 6 months; When treating infertility using in vitro fertilization (IVF): 3.75 mg IM once on the 2nd day of the menstrual cycle.
OVERDOSE Currently, no cases of overdose with Buserelin have been reported.
SPECIAL INSTRUCTIONS For women. Patients with any form of depression during treatment with the drug should be under close medical supervision. Ovulation induction should be performed under strict medical supervision. In the initial stage of treatment with the drug, the development of ovarian cysts is possible. Before starting treatment with the drug, it is recommended to exclude pregnancy and stop taking hormonal contraceptives, however, during the first two months of using the drug, it is necessary to use other (non-hormonal) methods of contraception. In men. In order to effectively prevent possible side effects in the first phase of the drug’s action, it is necessary to use antiandrogens two weeks before the first injection of buserelin depot and for two weeks after the first injection. Influence on the ability to drive a car and other mechanisms. Caution should be exercised when prescribing the drug to patients engaged in potentially hazardous activities that require increased attention and speed of mental and motor reactions.
STORAGE CONDITIONS Store in a place protected from light and out of reach of children, at a temperature of 8 to 20
Buserelin Depot Liof. 3.75 mg N1 vial. d/prig.susp.v/m with solution
Dosage For hormone-dependent prostate cancer - 3.75 mg IM every 4 weeks.
In the treatment of endometriosis, hyperplastic processes of the endometrium - 3.75 mg intramuscularly once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. Duration of treatment is 4-6 months.
For the treatment of uterine fibroids - 3.75 mg intramuscularly once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. The duration of treatment is 3 months before surgery, in other cases - 6 months.
When treating infertility using in vitro fertilization - 3.75 mg IM once at the beginning of the follicular phase (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. After blockade of pituitary function, confirmed by a decrease in the concentration of estrogen in the blood serum by at least 50% of the initial level (usually determined 12-15 days after injection of Buserelin-depot), in the absence of cysts in the ovaries (according to ultrasound), endometrial thickness no more than 5 mm, stimulation of superovulation begins with gonadotropic hormones under ultrasound monitoring and control of the level of estradiol in the blood serum.
Rules for preparing the suspension and administering the drug
The drug is administered only intramuscularly. A suspension for intramuscular injection is prepared using the supplied solvent immediately before administration. The drug should be prepared and administered only by specially trained medical personnel.
The bottle with Buserelin-depot should be kept strictly vertical. By lightly tapping the bottle, you need to ensure that all the lyophilisate is at the bottom of the bottle.
Open the syringe, attach a needle with a pink pavilion (1.2 × 50 mm) to it to withdraw the solvent.
Open the ampoule and draw the entire contents of the ampoule with solvent into the syringe, set the syringe to a dose of 2 ml.
Remove the plastic cap from the bottle containing the lyophilisate. Disinfect the rubber stopper of the bottle with an alcohol swab. Insert the needle into the bottle with the lyophilisate through the center of the rubber stopper and carefully introduce the solvent along the inner wall of the bottle, without touching the contents of the bottle with the needle. Remove the syringe from the bottle.
The bottle should remain motionless until the lyophilisate solvent is completely saturated with the solvent and a suspension is formed (approximately 3-5 minutes). After which, without turning the bottle over, you should check the presence of dry lyophilisate at the walls and bottom of the bottle. If dry residues of the lyophilisate are detected, leave the bottle until completely saturated.
Once there is no remaining dry lyophilisate left, the contents of the bottle should be carefully mixed in a circular motion for 30-60 seconds until a homogeneous suspension is formed. Do not invert or shake the bottle, as this may cause flakes to fall out and the suspension to become unusable.
You need to quickly insert the needle through the rubber stopper into the bottle. Then lower the cut of the needle down and, tilting the bottle at an angle of 45°, slowly draw the entire suspension into the syringe. Do not invert the bottle when taking it. A small amount of the drug may remain on the walls and bottom of the bottle. Consumption for the residue on the walls and bottom of the bottle is taken into account.
Immediately replace the needle with a pink pavilion with a needle with a green pavilion (0.8×40 mm), carefully turn the syringe over and remove air from the syringe.
Buserelin-depot suspension should be administered immediately after preparation.
Using an alcohol swab, you need to disinfect the injection site. Insert the needle deep into the gluteal muscle, then pull the syringe plunger back slightly to ensure that there is no damage to the vessel. Inject the suspension intramuscularly slowly with constant pressure on the syringe plunger. If the needle becomes clogged, it is replaced with another needle of the same diameter.
Buserelin
Rules for preparing the suspension and administering the drug. A suspension of the drug for intramuscular injection is prepared using the supplied solvent immediately before administration. The solvent is taken from the ampoule and transferred to the bottle using the included needle with a pink pavilion. The bottle is carefully shaken until a homogeneous suspension is obtained. The suspension is completely drawn into the syringe without inverting the bottle. The needle with the pink pavilion is replaced with a needle with the green pavilion, after which the injection is immediately given.
The drug is administered only intramuscularly. For hormone-dependent prostate cancer - 4.2 mg, IM once, every 4 weeks.
For endometriosis, hyperplastic processes of the endometrium - 4.2 mg, IM once, every 4 weeks; treatment begins in the first 5 days of the menstrual cycle; Duration of treatment - 4-6 months.
For uterine fibroids - 4.2 mg, intramuscularly once, every 4 weeks; treatment begins in the first 5 days of the menstrual cycle; Duration of treatment - 3 months before surgery, in other cases - 6 months.
When treating infertility using IVF - 4.2 mg intramuscularly once, on the 2nd day of the menstrual cycle.
Intranasally. When treating endometriosis, uterine fibroids, endometrial hyperplastic processes, the drug is administered into the nasal passages after cleansing them at a dose of 900 mcg/day. A single dose of the drug when the pump is fully pressed is 150 mcg. The daily dose is administered in equal portions, 1 dose into each nostril 3 times a day at equal intervals (6-8 hours) in the morning, afternoon and evening. Treatment with the drug should begin on day 1 or 2 of the menstrual cycle.
When treating infertility using IVF, 600 mcg/day is prescribed, i.e. 1 dose (150 mcg) into the nasal passage 4 times a day at regular intervals. The drug is administered from the middle of the luteal phase of the menstrual cycle (from 21-24 days of the cycle) until the day of administration of the ovulatory dose of hCG. Against this background, when the blockade of estradiol (E2) synthesis is achieved from 2-5 days of menstrual-like bleeding, stimulation with gonadotropin preparations is carried out according to standard schemes. In case of pronounced blockade of the reproductive system and a “weak” response of the ovaries to stimulation of ovulation with gonadotropin preparations, the daily dose of the drug should be reduced to 2 doses per day or the dose of gonadotropins increased.
A repeated course of treatment is carried out only after a medical examination under dynamic control of the hormonal profile and ultrasound monitoring.
Implant - subcutaneously, the contents of the Buserelin applicator (6.3 mg) are injected into the lateral surface of the abdomen once every 2 months.
Buserelin-depot
For hormone-dependent prostate cancer -
3.75 mg IM every 4 weeks.
In the treatment of endometriosis, endometrial hyperplastic processes
- 3.75 mg IM once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. Duration of treatment is 4-6 months.
In the treatment of uterine fibroids
- 3.75 mg IM once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. The duration of treatment is 3 months before surgery, in other cases - 6 months.
When treating infertility using in vitro fertilization -
3.75 mg IM once at the beginning of the follicular phase (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. After blockade of pituitary function, confirmed by a decrease in the concentration of estrogen in the blood serum by at least 50% of the initial level (usually determined 12-15 days after injection of Buserelin-depot), in the absence of cysts in the ovaries (according to ultrasound), endometrial thickness no more than 5 mm, stimulation of superovulation begins with gonadotropic hormones under ultrasound monitoring and control of the level of estradiol in the blood serum.
Rules for preparing the suspension and administering the drug
The drug is administered only intramuscularly. A suspension for intramuscular injection is prepared using the supplied solvent immediately before administration. The drug should be prepared and administered only by specially trained medical personnel.
The bottle with Buserelin-depot should be kept strictly vertical. By lightly tapping the bottle, you need to ensure that all the lyophilisate is at the bottom of the bottle.
Open the syringe, attach a needle with a pink pavilion (1.2 × 50 mm) to it to withdraw the solvent.
Open the ampoule and draw the entire contents of the ampoule with solvent into the syringe, set the syringe to a dose of 2 ml.
Remove the plastic cap from the bottle containing the lyophilisate. Disinfect the rubber stopper of the bottle with an alcohol swab. Insert the needle into the bottle with the lyophilisate through the center of the rubber stopper and carefully introduce the solvent along the inner wall of the bottle, without touching the contents of the bottle with the needle. Remove the syringe from the bottle.
The bottle should remain motionless until the lyophilisate solvent is completely saturated with the solvent and a suspension is formed (approximately 3-5 minutes). After which, without turning the bottle over, you should check the presence of dry lyophilisate at the walls and bottom of the bottle. If dry residues of the lyophilisate are detected, leave the bottle until completely saturated.
Once there is no remaining dry lyophilisate left, the contents of the bottle should be carefully mixed in a circular motion for 30-60 seconds until a homogeneous suspension is formed. Do not invert or shake the bottle, as this may cause flakes to fall out and the suspension to become unusable.
You need to quickly insert the needle through the rubber stopper into the bottle. Then lower the cut of the needle down and, tilting the bottle at an angle of 45°, slowly draw the entire suspension into the syringe. Do not invert the bottle when taking it. A small amount of the drug may remain on the walls and bottom of the bottle. Consumption for the residue on the walls and bottom of the bottle is taken into account.
Immediately replace the needle with a pink pavilion with a needle with a green pavilion (0.8x40 mm), carefully turn the syringe over and remove air from the syringe.
Buserelin-depot suspension should be administered immediately after preparation.
Using an alcohol swab, you need to disinfect the injection site. Insert the needle deep into the gluteal muscle, then pull the syringe plunger back slightly to ensure that there is no damage to the vessel. Inject the suspension intramuscularly slowly with constant pressure on the syringe plunger. If the needle becomes clogged, it is replaced with another needle of the same diameter.
